Intersect ENT prices IPO at $11, the low end of the range

By Renaissance Capital,

Shutterstock photo

Intersect ENT, which sells absorbable nasal implants for post-surgical sinusitis relief, raised $55 million by offering 5.0 million shares at $11, the low end of the range of $11 to $13. Intersect ENT plans to list on the NASDAQ under the symbol XENT. Intersect ENT initially filed confidentially on 5/2/2014. J.P. Morgan and Piper Jaffray acted as lead managers on the deal.

The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

This article appears in: News Headlines IPOs
Referenced Stocks: XENT

More from Renaissance Capital


Renaissance Capital

Renaissance Capital

Follow on:

Find a Credit Card

Select a credit card product by:
Select an offer:
Data Provided by